During its first full year in operation, GARDP developed a business plan that articulates a seven-year roadmap, prioritizing sepsis in newborns and STIs – two disease areas of high global public health need on which to focus our R&D efforts.
Our plans for 2018 are even more ambitious. These include: starting a global observational study, and two clinical trials; developing new public and private partnerships; accelerating our work to recover molecules for their potential value for antimicrobial drug development; and recovering and sharing the knowledge of established antimicrobial researchers with those starting their careers.
